This year’s Fraunhofer Symposium “Netzwert” was held on February 26 -27, 2019 in Munich. Prof. Dr. Dr. Gerd Geisslinger and Dr. Frank Behrens both presented the Fraunhofer CIMD.
At this year's Fraunhofer Symposium Netzwert 2019 “Momentum” two presentations featured the Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD. Prof. Dr. Dr. Gerd Geisslinger, institute director of Fraunhofer IME and spokesman of Fraunhofer CIMD, gave a presentation entitled »Immunmediated Diseases: Interdisciplinary Research for the Benefit of Patients, Fraunhofer Cluster of Excellence« in the session “Translational Medicine” on the first day of the symposium. On the following day, the Fraunhofer CIMD was presented in the session “Fraunhofer Cluster of Excellence” by Dr. Frank Behrens, scientific coordinator of Fraunhofer CIMD, in his lecture entitled ”Immunmediated Diseases: Immune Diseases - Multidisciplinary Challenges”.
Presentation of Prof. Dr. Dr. Gerd Geisslinger on February 26, 2019 in the session »Translational Medicine«
Fraunhofer is accelerating its activities in the growth market of health research in order to make a social contribution to the therapy of so far insufficiently treatable diseases and to counteract the rising costs in the health care system. With its diversity, the Fraunhofer-Gesellschaft is ideally suited to cover the decisive technologies in the fields of drugs, diagnostics, data and devices (“4D”), which focus on the patient. For example, the Cluster of Excellence for Immune-Mmediated Diseases (CIMD) aims to exploit synergies to develop new groundbreaking approaches for curative therapies against immune diseases.
Presentation of Dr. Frank Behrens on February 27, 2019 in the session »Fraunhofer Cluster of Excellence«
Immune diseases include a variety of diseases such as inflammatory rheumatic diseases, inflammatory skin and intestinal diseases, but also respiratory diseases, which have a significant pathophysiological similarity in the misregulation of the immune system. Although it is estimated that eight percent of the world's population is affected, it has not yet been possible to develop causal therapy principles to the point of application. Rather, only symptom-relieving drugs are currently offered. One reason for this is the variety of clinical symptoms and manifestations of these diseases, as well as the ability of the immune system to adapt to changes. The targeted development of innovative methods for the prevention, diagnosis and therapy of immune diseases therefore requires interdisciplinary networking far beyond biomedicine (“4D”).
Fraunhofer Cluster of Excellence Immune-Mediated Diseases